While they are often mentioned together, BPC-157 and TB-500 are fundamentally different peptides with distinct origins, structures, and areas of scientific interest
The primary contraindication is a personal history of cancer, since its growth hormone-stimulating mechanism is not appropriate for patients with any oncological history
They are classified as research compounds, meaning they are not approved for human use in any form
However, a common regimen involves one ampoule (3 ml) administered once daily or 2-3 times per week, depending on the clinical picture
In contrast, the Aviscera Bioscience high-sensitivity BDNF ELISA kit (#SK00752-01) and the FineTest human BDNF ELISA kit (#EH0043), also marketed for measuring mature BDNF, showed a higher reactivity to pro- than to mature BDNF (Figs